AC Immune SA
(NASDAQ : ACIU)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. 0.65%40.350.9%$2406.88m
JNJJohnson & Johnson 0.83%150.240.7%$1152.56m
ABBVAbbVie, Inc. 2.42%107.271.9%$937.70m
MRKMerck & Co., Inc. 0.57%81.910.7%$681.87m
BMYBristol-Myers Squibb Co. 0.85%62.311.0%$627.96m
LLYEli Lilly & Co. 3.05%148.501.1%$611.14m
AZNAstraZeneca Plc 1.82%53.741.2%$375.21m
TTNPTitan Pharmaceuticals, Inc. -3.85%3.5017.1%$266.44m
GSKGlaxoSmithKline Plc 0.62%37.500.2%$214.98m
NVSNovartis AG 1.52%91.610.2%$191.99m
ARCTArcturus Therapeutics Holdings, Inc. 12.79%112.010.0%$146.59m
RGENRepligen Corp. 0.60%188.337.1%$92.93m
SBTXSilverback Therapeutics, Inc. 19.05%25.000.0%$88.29m
KNTEKinnate Biopharma, Inc. 11.35%43.460.0%$86.26m
NVONovo Nordisk A/S 0.89%67.810.1%$83.43m

Company Profile

AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.